BioSpace News Archive

Valbiotis, a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, is accelerating its marketing strategy.

Waters Corporation announced a combined investment of up to €6 million with support from IDA Ireland to expand its operations in Drinagh, Wexford to fund research and development of new clinical diagnostics products.

MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced the closing of its previously announced registered direct and PIPE offerings.

Humana Inc., one of the nation’s leading health and well-being companies, announced the Medicare Star Ratings for its Medicare Advantage plans, effective Jan. 1, 2023, from the Centers for Medicare and Medicaid Services.

CytoSorbents Corporation announced today that its Chief Financial Officer, Kathleen P. Bloch , MBA, CPA, plans to retire on March 31, 2023 at age 68, following a distinguished decade-long career at the Company.

Bristol Myers Squibb (NYSE:BMY) announced that it has changed the dial-in and replay information of its previously announced third quarter 2022 earnings conference call scheduled for Wednesday, October 26, 2022.

BridgeBio will host an investor call on October 17, 2022 at 1:30 pm ET to discuss the data and next steps for its two lead RAS programs.

Endo International plc (OTC: ENDPQ) announced today that data from studies of Endo Aesthetics’ Qwo ® (collagenase clostridium histolyticum-aaes), an FDA-approved injectable for the treatment of moderate to severe cellulite in the buttocks of adult women, will be presented during the American Society for Dermatologic Surgery annual meeting.

BridGene Biosciences, Inc. today announced that two abstracts featuring the application of the company’s proprietary chemoproteomic platform IMTAC,

TwinStrand Biosciences, Inc. today announced that the company has implemented a reorganization designed to sustain growth through a focus on key commercial initiatives.